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AbstrAct
Autophagy is a cellular degrading process that promotes tumor cell survival or 
cell death in cancer, depending on the progress of oncogenesis. Protein light chain 3 
(LC3) and p62/SQSTM1 (p62) are associated with autophagosomal membranes that 
engulf cytoplasmic content for subsequent degradation. We studied LC3 and p62 
expression using immunohistochemistry in a large cohort of 466 stage I/II non-small 
cell lung cancer (NSCLC) using a tissue microarray. We evaluated dot-like cytoplasmic 
expression of LC3 and dot-like, cytoplasmic and nuclear staining for p62 in relation 
to clinico-pathological parameters.
LC3 expression correlated with all p62 patterns, as those correlated among 
each other (p < 0.001 each). There was no correlation with stage, age or gender. A 
combination of high LC3/high p62 dot-like staining (suggesting impaired autophagy) 
showed a trend for better outcome (p = 0.11). Interestingly, a combined low 
cytoplasmic/low nuclear p62 expression regardless of dot-like staining was an 
independent prognostic factor for longer survival (p = 0.006; HR=1.96), in addition 
to tumor stage (p = 0.004; HR=1.4). 
The autophagy markers LC3 and p62 are differentially expressed in NSCLC, 
pointing towards a biologically significant role. High LC3 levels seem to be linked 
to lower tumor aggressiveness, while high general p62 expression was significantly 
associated with aggressive tumor behavior. 
IntroductIon
Lung cancer is one of the most frequent cancers, 
and responsible for the most deaths due to malignant 
disease. The desire for better understanding its biology, 
which could ideally confer additional, better and more 
precise oncological therapeutics, is thus enormous. Non-
small cell lung cancer (NSCLC) comprises the majority 
of lung carcinomas. Most of NSCLC can be histologically 
typed as adenocarcinoma (AC), squamous cell carcinoma 
(SqCC) or large cell carcinoma (LCC), as defined by the 
WHO [1].
The cellular process of autophagy has many 
functions including bulk degradation of cytoplasmic 
content to ensure homeostasis [2], degradation of 
superfluous or damaged organelles [3] and the engulfment 
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of pathogens [4]. The role of autophagy in cancer is 
complex and depends on tumor stage, type and the driving 
oncogene [5-7]. Under homeostatic conditions autophagy 
is regarded as a tumor suppressor process, but there is 
evidence it is later on required for tumor progression [8, 
9].
Exploiting autophagy for anti-cancer therapeutic 
benefit is an area gaining ever increasing focus. 
On a cellular level autophagy aims at degrading 
cytoplasmic content in the lysosomal compartment [2]. 
Macroautophagy, referred to as autophagy from here 
on, is hallmarked by the formation of double-membrane 
vesicles, so-called autophagosomes, which finally fuse 
with lysosomes to degrade their content [10].
On a molecular level several functional complexes, 
comprising so-called autophagy related (ATG) genes, are 
involved in autophagosome biogenesis, cargo recognition 
and in mediating autophagosome-lysosome fusion. Briefly, 
the unc-51-like kinase 1 (ULK1) complex is important 
for autophagy initiation. Down-stream of the ULK-1 
complex the coiled-coil myosin-like BCL2-interacting 
protein (Beclin1) complex is generating phosphoinositol-
3-phosphates (PI3Ps), allowing for the recruitment of 
other ATG proteins [11]. Furthermore, two ubiquitin-like 
systems are required for vesicle elongation and cargo 
recognition, namely the ATG12-ATG5- and the ATG8-
conjugation system. The latter one serves to lipidate ATG8 
family members, including microtubule-associated protein 
1 light chain 3 (MAP1LC3 or LC3, hereafter referred to 
as LC3) [12, 13]. LC3 comprises three isoforms LC3A, B 
and C. Since LC3 is incorporated into the inner and outer 
membrane of autophagosomes [14], its detection allows 
for monitoring the autophagy pathway [15]. LC3-I is 
cytosolic, whereas the lipidated form LC3-II is membrane 
bound [14].
Autophagy can either be non-selective or can very 
specifically target certain portions of the cytoplasm for 
degradation [16]. Different autophagy receptors are 
mediating selectivity by being able to interact with the 
cargo on the one hand and the autophagy machinery on 
the other hand [17]. The best studied is sequestosome 1 
(SQSTM1 or p62, hereafter referred to as p62). Essential 
for its function as an autophagy receptor is its ability to 
interact with ubiquitinated cargo and LC3B [18]. During 
this process p62 itself is constantly degraded. Reduced 
levels of p62 are therefore associated with an activated 
autophagy pathway [15]. 
Both LC3 and p62 are frequently used as markers 
to assess autophagy [15]. Although autophagy is a flux, 
and should ideally be measured in functional assays, 
immunohistochemistry is the method of choice for tissue 
based retrospective analysis of large cohorts. Thereby, 
dot-like staining of LC3 serves as a surrogate marker 
for autophagic vesicles. As p62 is constantly degraded 
in autolysosomes, it is a surrogate marker for autophagic 
degradation. 
In NSCLC, there are only very few studies on the 
prognostic significance of the expression of autophagy 
markers, and all have been conducted in broad stage 
collectives [19, 20]. Because the role of autophagy in 
cancer may be stage dependent, the aim of our present 
study was to assess autophagy-associated markers in non-
metastasized, early-stage NSCLC.
results
staining patterns
Formalin-fixed and paraffin embedded (FFPE) tissue 
of 466 primary resected, chemotherapy-naïve, early-stage 
NSCLC was analyzed for the expression of autophagy 
associated markers LC3 and p62. The anti-LC3 antibody 
from Novus (N) is known to recognize the LC3 isoforms 
A and B [21] the anti-LC3B antibody from Cell Signaling 
(CS) is isoform B specific [22]. 
Staining of both antibodies could be assessed in 442 
cases, and correlated significantly (p < 0.0001), although 
the CS antibody showed a generally weaker staining, with 
few positive cases. LC3 (CS) dot-like staining could be 
evaluated in 464 cases: score 0 in 403 cases (86.9%), score 
1 in 47 cases (10.1%), score 2 in 11 cases (2.4%), score 3 
in 3 cases (0.6%).
LC3 (N) dot-like staining could be evaluated in 443 
cases and was observed as score 0 in 240 cases (54.2%), 
score 1 in 120 cases (27.1%), score 2 in 48 cases (10.8%) 
and score 3 in 35 cases (7.9%)(Figure 1A). Stone-like 
structures (SLS)[20] were present in 8 cases (1.8%). 
For p62 dot-like staining, 420 punches were suitable for 
evaluation, and 328 cases (78.1%) scored 0, 59 cases 
(14%) scored 1, 24 cases (5.7%) scored 2 and 9 cases 
(2.1%) scored 3. SLS were present in 14 cases (3.3%). 
Cytoplasmic staining of p62 was absent (score 0) in 82 
cases (19.5%), score 1 in 266 cases (63.3%) and score 2 
in 72 cases (17.1%). Nuclear staining was absent in 264 
cases (62.9%) and present in 156 cases (37.1%).
LC3 dot-like staining showed a significant 
correlation with all p62 staining patterns (p < 0.001 each), 
and all p62 staining patterns correlated among each other 
(p < 0.001 each). Examples for p62 cytoplasmic, dot-like, 
nuclear and SLS staining are shown in Figure 1B.
Assessment of staining heterogeneity was performed 
in 38 exemplary cases, using 8 punches from two tissue 
blocks of each tumor. Completely homogenous staining 
with regard to score 1 to 3 was observed in 12/38 cases 
(31.6%) for LC3 dot-like staining, 13/38 cases (34.2%) 
for p62 dot-like staining, 18/38 cases (47.4%) for p62 
cytoplasmic staining and 19/38 cases (50%) for p62 
nuclear staining. Heterogeneous staining, however, with 
a deviation of > 1 scoring points in > 1 spot, that would 
also have caused a different classification into „low“ and 
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Figure 1: Immunohistochemical staining of lc3 and p62. A. LC3 (Novus) staining patterns of the 22 cases further analysed 
by immunoblot analysis (figure 2). Results of dot-like staining patterns are given in the upper panels of figure 2A and B for each case. b. 
Examples of p62 staining, with cytoplasmic, dot-like, nuclear and SLS staining patterns. (original magnification 400 x, scale bar 100 µm; 
insets: original magnification 1000 x, scale bar 20 µm).
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„high“ as described below (refer to following paragraph 
Correlation with clinico-pathologic parameters) was 
observed in only 2/38 cases (5.3%) for LC3 dot-like 
staining, 1/38 cases (2.6%) for p62 dot-like staining, no 
case for p62 cytoplasmic staining and 1/38 cases (2.6%) 
for p62 nuclear staining.
Immunoblot analysis
During the process of autophagosome formation 
LC3 gets cleaved and lipidated before incorporation into 
the membrane. This modification enables to distinguish 
between cytosolic LC3 (LC3-I) and membrane-bound 
LC3 (LC3-II) on a western blot [23]. Immunoblot analysis 
of 22 cases selected according to absent and strongly 
present LC3 dot-like staining revealed the feasibility of 
this methodology for LC3 evaluation in FFPE tissue. The 
results correlated mostly with the immunohistochemical 
staining patterns as depicted in Figure 1 versus 2. 
Importantly, both LC3 antibodies (from Novus and Cell 
Signaling) showed equal results on Western Blot (Figure 
2).
correlation with clinico-pathologic parameters
For the purposes of correlation with pathological 
and clinical parameters, immunohistochemistry scores 
were categorized as either “low” or “high” for each 
staining pattern according to our established protocol [24] 
with slight modifications, following the prognostic impact 
of the single scores: For LC3 dot-like staining scores 0 
and 1 were classified as low, scores 2 and 3 as high. For 
p62 dot-like staining score 0 was classified as low, scores 
1, 2 and 3 were interpreted as high. For p62 cytoplasmic 
table 1: lc3 (novus) and p62 dot-like staining and clinico-pathologic parameters (total n = 466; for evaluation lc3 
n = 443; p62 n = 420).
parameter total lc3 dot-like staining p62 dot-like staining
n (%) low high p low high p
total 466 (100) 360 83 328 92
age
<67 years 247 (53) 191 47
0.556
169 53
0.302
≥ 67 years 219 (47) 169 36 159 39
gender
male 343 (73.6) 276 53 0.016
237 68
0.753
female 123 (26.4) 84 30 91 24
histology
AdCA 202 (43.3) 146 48
0.017
144 38
0.463SqCC 229 (49.1) 186 30 164 45
LCC 35 (7.5) 28 5 20 9
pt category
1a 24 (5.2) 17 4
0.789
14 6
0.108
1b 31 (6.7) 23 4 13 9
2a 304 (65.2) 233 59 217 61
2b 68 (14.6) 56 9 52 9
3 39 (8.4) 31 7 32 7
uIcc stage
IA 55 (11.8) 40 8
0.666
27 15
0.076
IB 304 (65.2) 233 59 217 61
IIA 68 (14.6) 56 9 52 9
IIB 39 (8.4) 31 7 32 7
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Figure 2: Immunoblot analysis of lc3 in protein extracts from FFPe tissue from 22 early-stage non-small cell lung 
carcinomas. A. Immunoblot analysis of LC3-I (cytosolic) and LC3-II (membrane-bound) of cases 1 to 12, and b. cases 13 to 22, using 
anti-LC3 Novus (middle panel) and anti-LC3B Cell Signaling (bottom panel) primary antibodies. Total protein was visualised and used 
as loading control. Immunohistochemistry scores for anti-LC3 Novus and anti-LC3B Cell Signaling primary antibodies are shown in the 
tables (upper panel). 
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staining scores 0 and 1 were classified as low and score 2 
as high. Only 14 cases (3%) showed high dot-like staining 
using LC3 (CS), 83 cases (18.7%) using LC3 (N).
Low LC3 (N) dot-like staining was more frequent 
in males (p = 0.016) and SqCC (p = 0.017). There was 
no association with age (median), pT category or stage 
(Table 1). There was no significant association with the 
abovementioned factors for p62 dot-like staining or the 
presence of LC3 positive or p62 positive SLS. In contrast, 
lower p62 cytoplasmic and nuclear stainings were more 
frequent in AC (p = 0.029 and p < 0.001, respectively; 
Table 2).
survival analysis
Survival data was available for 349 patients. 
Survival analysis showed a better overall survival (OS) 
and recurrence free survival (RFS) for younger patients 
(cut-off median; OS p = 0.002; RFS p = 0.012), for 
females (OS p = 0.06; RFS p = 0.035), for patients with 
AC and LCC (OS p = 0.005; RFS p = 0.025), and with 
lower pT categories/UICC stages (OS p = 0.004/p = 0.003; 
RFS p = 0.018/p = 0.137; respectively).
None of the patients with high LC3 (CS) dot-like 
staining relapsed or died, but short follow up times in this 
sub-group preclude any conclusions and further analyses.
For LC3 (N), high dot-like staining patterns were 
in trend linked to a better OS (p = 0.16), similar to high 
p62 dot-like staining (p = 0.28), but not to RFS (p = 0.49; 
table 2: p62 cytoplasmic and nuclear staining and clinico-pathologic parameters (total n=466; for evaluation n=420).
parameter total p62 cytoplasmic staining p62 nuclear staining
n (%) low high p absent present p
total 466 (100) 348 72 264 156
age
<67 years 247 (53) 187 35
0.428
143 79
0.442
≥ 67 years 219 (47) 161 37 121 77
gender
male 343 (73.6) 247 58 0.097
185 120
0.140
female 123 (26.4) 101 14 79 36
histology
AdCA 202 (43.3) 161 21
0.029
134 48
<0.001SqCC 229 (49.1) 164 45 112 97
LCC 35 (7.5) 23 6 18 11
pt category
1a 24 (5.2) 17 3
0.113
13 7
0.942
1b 31 (6.7) 15 7 15 7
2a 304 (65.2) 233 45 173 105
2b 68 (14.6) 47 14 38 23
3 39 (8.4) 36 3 25 14
uIcc stage
IA 55 (11.8) 32 10
0.145
28 14
0.894
IB 304 (65.2) 233 45 173 105
IIA 68 (14.6) 47 14 38 23
IIB 39 (8.4) 36 3 25 14
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p = 0.855). The presence of SLS was not associated with 
survival. In contrast, low p62 cytoplasmic staining was 
significantly associated with a better tumor related OS (p 
= 0.036), similar to negative p62 nuclear staining (trend; 
p = 0.066)(Figure 3), but not with RFS (p = 0.091; p = 
0.536, respectively).
According to previously published work [25] a 
combination of LC3 and p62 dot-like staining patterns was 
analyzed: A small subgroup of tumors with both high LC3 
and p62 dot-like staining (n = 31) was associated with a 
better OS. In contrast, high LC3/low p62 dot-like pattern 
(n = 18) and low LC3/any level of p62 dot-like pattern (n 
= 300) had a similarly unfavorable prognostic impact (p = 
0.11) (Figure 3). This trend was not demonstrated for RFS 
(p = 0.514).
For p62 cytoplasmic and nuclear staining, subgroups 
were built according to a different recently published paper 
[26]. Tumors with both p62 low cytoplasmic and nuclear 
staining (n = 185) were associated with a significantly 
better OS and RFS than mixed (n = 139) and both high 
cytoplasmic and nuclear stained tumors (n = 25) (OS p = 
0.005; RFS p = 0.008)
In multivariate analysis including UICC pT 
category/UICC stage, histological subtype, age, gender 
and p62 cytoplasmic/nuclear staining, only pT category/
UICC stage and low p62 cytoplasmic/nuclear staining 
were independent prognostic factors for OS (HR = 1.96; 
95%CI 1.2-3.2; p = 0.006)(Table 3) and RFS (HR = 1.655; 
95% CI; 1.1-2.4; p = 0.011). 
dIscussIon
We investigated a homogeneous, large early-stage 
NSCLC cohort of 466 patients for the expression of the 
autophagy markers LC3 and p62, using a previously 
validated immunohistochemical protocol [24]. The 
observed differential expression of both markers points 
towards a biologically significant role in NSCLC, although 
drawing conclusions from the staining patterns on specific 
disruptions of the autophagy mechanism in the tumors is 
not clear-cut.
A trend for better tumor related OS was seen in 
tumors expressing high dot-like staining of both LC3 and 
p62, which in a simplified model could imply impairment 
at late stages of the autophagy cascade. The low number 
of tumors expressing high LC3 in our cohort may have 
precluded statistical significance although the results may 
be valid and important. Corroborating studies are therefore 
justified. Contrary to the reported adverse prognostic 
significance of SLS in the SqCC subgroup of NSCLC, 
using antibodies to the LC3 isoform LC3A [20], detection 
of SLS was rare and not associated with outcome in our 
cohort.
p62 serves as a link between LC3B and ubiquitinated 
substrates to be degraded in autolysosomes, rendering it a 
surrogate marker for degradation [15]. Thus, high LC3/
low p62 dot-like pattern may be indicative of activated and 
intact autophagy, and low LC3/p62 any dot-like pattern 
may show low basal autophagy [25]. Those staining 
patterns had similarly unfavorable prognostic impact in 
our collective. However, it is questionable if drawing 
conclusions from steady-state levels of autophagy markers 
on the functional state of autophagic activity is a valid 
approach. As very recently updated, the methodology to 
assess this highly dynamic process on human FFPE tissue 
still needs significant improvement [15]. LC3 puncta may 
mean activated autophagy, but also impaired autophagy 
due to a late stage block. Second, all autophagy markers 
may be associated with non-autophagic structures. 
Interestingly though, it was high p62 cytoplasmic/
nuclear expression that emerged as an independent 
factor for shorter tumor related OS and RFS, regardless 
of histological subtype. This is in line with Inoue et al., 
who reported high cytoplasmic expression of p62 to be 
an independent marker for worse prognosis among AC 
(n = 72), in a cohort of 109 NSCLC, without specifying 
for nuclear positivity [19]. Similar correlations of high 
cytoplasmic p62 expression and adverse clinical features 
were also found in other cancer types, such as breast 
cancer [27, 28], prostate cancer [29] and oral SqCC 
[25]. It is important to note, that this cytoplasmic and 
nuclear expression of p62 may not necessarily be linked 
to autophagy. One alternative candidate effector may be 
the NRF2-KEAP1-pathway. Several groups could show 
that high levels of p62 lead to Nrf2 stabilization and 
subsequent transcription of genes with an antioxidant 
function [30]. Importantly, persistent activation of Nrf2 
via p62 stabilization contributes to tumor progression [31]. 
However, in the study by Inoue et al. accumulation of p62 
table 3: Multivariate analysis for tumor related overall survival.
parameter Hr
95% confidential interval
p-value
min max
Age (median) 1.574 0.982 2.525 0.06
Gender 0.72 0.39 1.33 0.294
Histology 1.148 0.765 1.723 0.504
pT category 1.407 1.117 1.772 0.004
p62 cytoplasmic/nuclear 1.962 1.217 3.164 0.006
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Figure 3: survival analysis. Kaplan Meier curves for tumour related overall survival assessed for A. LC3 and b. p62 dot-like staining, 
c. cytoplasmic and d. nuclear p62 staining, e. a combination of LC3/p62 dot-like staining (HH = both high, LL = both low, HL = high 
LC3/low p62, LH = low LC3/high p62), and F. a combination of p62 cytoplasmic and nuclear staining (HH = both high, LL = both low, HL 
= high cytoplasmic, low nuclear, LH = low cytoplasmic, high nuclear).
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did not necessarily result in the stabilization of NRF2 
[19]. Because increased p62 was shown to lead to NFκB-
activation [32, 33], another explanation for worse outcome 
may be the potentiation of NFκB-dependent transcription 
via p62 [19]. 
Whereas the cytoplasmic function of p62 is 
well studied its nuclear function remains less clear. 
It has been shown that p62 is a protein able to rapidly 
shuttle between nucleus and cytoplasm, although its 
preferential localization under homeostatic conditions 
is cytoplasmic. In the nucleus p62 strongly co-localizes 
with PML-bodies and is probably involved in delivering 
ubiquitinated proteins for degradation [34]. Furthermore, 
p62 is involved in recruiting ALFY, a crucial factor for 
autophagic degradation of protein aggregates, from the 
nucleus to the cytoplasm [35]. It might well be that p62 
is involved in recruiting other proteins to the cytoplasm 
as well. 
It remains to be investigated whether accumulation 
of p62 in the nucleus is cancer cell-specific, and if so, what 
functional consequences it may have. Mislocalization of 
proteins in cancer cells is seen quite often. The best known 
is probably the predominant nuclear localization of NFκB 
in many cancer types [36].
In summary, this is the largest study to date reporting 
the expression of autophagy related markers LC3 and p62 
in a well-defined, early-stage NSCLC cohort of 466 cases. 
We report the correlation of dot-like immunohistochemical 
staining for LC3 with LC3-II protein expression assessed 
by immunoblot analysis of the same FFPE archival cases, 
corroborating the feasibility to assess autophagy structures 
using immunohistochemistry. 
We observed a trend for better outcome in tumors 
with high dot-like staining of LC3 and p62, being 
surrogates for autophagic vacuoles and thus the process 
of autophagy, although low numbers of this subgroup 
might have precluded statistical significance. Multivariate 
analysis rendered cytoplasmic/nuclear p62 staining an 
independent predictor of worse outcome, regardless of 
LC3 expression.
Our results warrant further investigations concerning 
the link between expression data and functional autophagy 
states and a possible non-autophagy related role of p62 in 
NSCLC.
MAterIAls And MetHods
Patient cohort
The retrospective study included patients with 
primary resected node-negative early-stage NSCLC 
(UICC 7th edition 2009 stage IA-IIB)[37], treated 
with curative surgery and diagnosed at the Institute 
of Pathology, University of Bern, Switzerland and 
the Institute of Pathology, University Hospital Basel, 
Switzerland between January 1988 and August 2008. The 
detailed staging work-up for this cohort of 544 patients has 
already been reported [38]. After exclusion of cases with 
lymph node metastases, neoadjuvant treatment, rare tumor 
types other than AC, SqCC and LCC, and insufficient 
tumor tissue for further analysis, 466 patients were finally 
included. This retrospective study was approved by the 
local ethics committee. 
Median age of the patient cohort was 67 years 
(range; 39-83 years). The detailed distribution of clinic-
pathologic characteristics can be seen in Tables 1 and 
2. The median RFS was 110 months (95% CI; 85-134 
months). Tumor related OS, which was calculated from 
the day of surgical resection until last contact or tumor 
specific death, was 186 months (95% CI; 119-252 
months). 
tissue microarray 
A tissue microarray (TMA) was constructed as 
reported elsewhere [38]. In short, formalin fixed paraffin 
embedded (FFPE) tissue blocks were retrieved from 
the archives of the Institutes of Pathology. One punch 
(diameter 0.6 mm) from the tumor center of the best-
preserved block was transferred to the receptor TMA-
block. 
To assess for staining heterogeneity, 38 patients with 
positive and negative LC3 staining patterns were selected 
from the Bern sub-cohort. A TMA was constructed as 
reported elsewhere [39], using 8 cores (diameter 0.6 mm) 
from 2 FFPE blocks per tumor. Additional punches (4 x 1 
mm per tumor) were taken for protein extraction.
Immunohistochemistry
Immunohistochemical staining was performed using 
the automated system BOND RX (Leica Biosystems, 
Newcastle, UK). TMA sections were cut at 4 μm, 
deparaffinized and rehydrated in dewax solution (Leica 
Biosystems). Endogenous peroxidase activity was blocked 
with H2O2 solution for 4 minutes.
All samples were incubated with the following 
primary antibodies for 30 minutes at room temperature 
(RT), as described before [24]: LC3B from Cell Signaling 
Technology (MA, USA, #3868, clone D11, dilution 
1:3000), LC3 from Novus Biologicals (Cambridge, UK, 
#NB600-1384, dilution 1:3000) using Tris buffer (pH 9) 
at 95°C for 30 minutes for antigen retrieval, p62 from 
MBL (IL, USA, #PM045, dilution 1:8000) using Citrate 
buffer (pH 6.5) at 100°C for 30 minutes for antigen 
retrieval. Antibody detection was done with the Bond 
Polymer Refine Detection kit (Leica Biosystems, DS9800) 
following the manufacturer’s instructions. 
Read out of stainings was performed by AMS and 
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SB as established before [24], and discrepancies were 
discussed on a multi-header microscope to gain a final 
consensus.
Dot-like staining patterns for LC3 and p62 were 
scored as: 0 - no dots or barely visible dots in < 5% of 
cells, 1 - detectable dots in 5-25% of cells, 2 readily 
detectable dots in 25-75% of cells and 3 - dots in > 75% 
of cells. Stone like structures (SLS) [20] were recorded 
separately. 
Cytoplasmic p62 staining was scored as: 0 - no 
or very faint staining, 1 - weak staining, 2 - moderate to 
strong staining. Nuclear p62 staining was recorded as 
present or absent. 
Images were acquired using a Zeiss Axioplan 2 
microscope (objective magnification 40 x and 100 x) and 
Axiovision software.
Immunoblot analysis
Protein was extracted from 4 x 1 mm tumor punches 
using the Qproteome FFPE Tissue Kit (Qiagen, 37623) 
as per manufacturer’s instruction. The samples were 
deparaffinized and rehydrated using Xylene followed by 
descending alcohol series. 100 μl of extraction buffer, 
containing β-mercaptoethanol, was added to each sample 
followed by ice (15 minutes) and heat treatment (100°C, 
20 minutes; 80°C, 2 hours).
Samples were centrifuged and supernatant 
transferred to a new tube. Protein concentration was 
determined using the Bradford protein assay (BioRad, 
Cressier, Switzerland). 30 μg of total protein were 
denatured in 5 x self-made sample buffer, containing 
β-mercaptoethanol (Sigma Aldrich, M-7522, Leiden, 
Netherlands), at 95°C for 5 minutes. Samples were loaded 
and separated on a 4-20% stain-free pre-cast gel (BioRad). 
Total protein was visualized as loading control. Separated 
protein was transferred onto a polyvinylidene difluoride 
membrane using the Trans-Blot® Turbo™ Transfer 
system (BioRad). Membranes were blocked in 5% bovine 
serum albumin (BSA)/tris-buffered saline (TBS) for 1 
hour at RT. The same primary antibodies were used as 
for immunohistochemistry in a working concentration 
of 1:1000 in 5% milk/TBS with 0.1% Tween (Sigma 
Aldrich, P9416). Membranes were incubated with primary 
antibodies over night at 4°C with shaking. Subsequently, 
membranes were incubated with anti-rabbit IgG, HRP-
linked Antibody (Cell Signaling, 7074, dilution 1:10 000 
in 5% milk/TBS-T) for 3 hours at RT with shaking. Prior 
to visualization, membranes were incubated with Clarity 
Western ECL Substrate (BioRad) for 5 minutes at RT with 
shaking. Results were visualized using the ChemiDoc™ 
MP system (BioRad). 
statistical analysis
Descriptive and comparative statistical analyses 
were performed using the SPSS 23 software (SPSS 
Inc, Chicago, IL, USA). Associations between staining 
patterns and clinico-pathologic parameters were evaluated 
using simple cross tabs (Chi2-test or Fisher’s exact test). 
Survival analysis was performed using log rank test and 
Cox regression analysis. The significance level was set at 
0.05.
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